← Back to Search

Intrauterine Device

Group 1 for Birth Control

Phase 4
Waitlist Available
Led By Stephanie Reich, MD
Research Sponsored by CooperSurgical Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment to end of treatment at 3 months
Awards & highlights

Study Summary

This trial will show that a new device for inserting Paragard® IUS is successful and safe.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment to end of treatment at 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment to end of treatment at 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Successful Insertions
Secondary outcome measures
Adverse Events
Adverse Events related to Procedure
IUS Expulsions and Dislocations
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Group 1Experimental Treatment1 Intervention
Paragard® T380A Intrauterine Copper Contraceptive with new inserter Non parous and parous female subjects of child bearing potential
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Paragard® T380A Intrauterine Copper Contraceptive with New Inserter
2022
Completed Phase 4
~120

Find a Location

Who is running the clinical trial?

CooperSurgical Inc.Lead Sponsor
3 Previous Clinical Trials
534 Total Patients Enrolled
Stephanie Reich, MDPrincipal InvestigatorCentral Austin - Women Partners in Health
Carol Stamm, MDPrincipal InvestigatorDowntown Women's Healthcare

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Assess the Safety of a New Inserter Device for Paragard® (Intrauterine Copper Contraceptive)
2022. "A Study to Assess the Safety of a New Inserter Device for Paragard® (Intrauterine Copper Contraceptive)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05309694.
~39 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top